

Paxman publishes newsletter on the company's relaunch in the Canadian market

Today, Paxman publishes the September issue of its newsletter aimed at shareholders, investors and other interested parties.

This month's issue highlights that Paxman is relaunching its Canadian business, with a new business model similar to the one being used in the United States. The company will also use a more direct approach, with patient technicians to support patients on site. 30+ patients have been treated so far, and scalp cooling systems have been installed at three cancer centers in Toronto.

The newsletter also includes information on that 10 units of Paxman's CIPN system will be delivered to National University of Singapore (NUS) before the end of the months for initial testing on healthy volunteers, that the company's Italian distribution partner Praesidia has ordered 10 PSCS2 systems, and CEO Richard Paxman answers shareholder questions on the Q2 interim report.

To read the newsletter and subscribe for upcoming issues, follow this link:

<http://bit.ly/paxsep21en>

Paxman's investor newsletter is published monthly as a part of the company's effort to strengthen its market communication together with the IR communication agency [Honeybadger](#). Every published issue of the newsletter is available on Paxman's website for investors, www.paxman.se. The company encourages feedback and requests on topics for upcoming issues of the newsletter.

Contacts

Richard Paxman, CEO
Tel: +44 7968 020641
Email: richard@paxmanscalpcooling.com
www.paxman.se

About Us

The Paxman Scalp Cooling System has been developed by the Paxman family to reduce hair loss in breast cancer patients undergoing chemotherapy. The concept behind the system came when the mother of four, Sue Paxman, experienced first-hand the trauma of chemotherapy-induced hair loss. With close to 3,500 systems delivered in to hospitals, clinics and treatment centres around the world, PAXMAN is the leading supplier of Scalp Cooling technology. PAXMAN's scalp-cooling cap is made from lightweight, biocompatible silicone that is soft and flexible, providing a snug yet comfortable fit during treatment. PAXMAN AB (publ) has its headquarters in Karlshamn (Sweden), with subsidiaries in Huddersfield (UK) and Houston, Texas (US).

The PAXMAN share is listed on Nasdaq First North Growth Market. FNCA Sweden AB is the company's Certified Adviser and can be contacted via info@fnca.se and +46 (0)8 528 003 99.

Attachments

[Paxman publishes newsletter on the company's relaunch in the Canadian market](#)